Healthcare / Diagnostics & ResearchNasdaqCM
$0.31
+0.02 (+6.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-27.1M · quality 32.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
18.1x
↑ROE
-50.4%
↓Gross Margin
23.6%
↓Debt/Equity
3.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+21.2%
FCF CAGR
—
FCF margin
-5.3%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $513.0M · net income $-68.6M · FCF $-27.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $513.0M | $513.0M | $490.7M | $572.4M | $547.7M | $89.6M | $60.5M | $43.6M | $26.3M | $24.2M | $20.4M | $22.7M | $24.6M | $22.1M | $28.2M | $33.1M | $28.8M |
| Net Income | $-68.6M | $-68.6M | $-108.4M | $-105.1M | $-337.0M | $10.9M | $-4.7M | $-790000.00 | $-194000.00 | $884000.00 | $-3.2M | $1.1M | $-1.1M | $773000.00 | $-6.3M | $2.3M | $-2.7M |
| EBITDA | $24.8M | $24.8M | $-26.8M | $-26.5M | $-273.4M | $650000.00 | $1.0M | $2.6M | $1.9M | $3.0M | $-1.5M | $2.3M | $1.9M | $2.6M | $-3.4M | $3.4M | $326000.00 |
| EPS | -2.11 | -2.11 | -4.19 | -4.10 | -13.84 | 0.19 | -0.43 | -0.08 | -0.02 | 0.10 | -0.40 | 0.07 | -0.13 | 0.09 | -0.88 | -0.74 | -0.55 |
| Gross Margin | 23.6% | 23.6% | 22.7% | 31.8% | 28.7% | 33.7% | 30.2% | 32.2% | 30.8% | 31.8% | 21.6% | 33.0% | 32.4% | 32.0% | 24.2% | 31.7% | 25.5% |
| Operating Margin | -7.2% | -7.2% | -11.1% | -1.6% | 3.7% | -6.3% | -5.1% | -0.4% | 0.1% | 5.3% | -14.9% | 4.0% | 1.4% | 3.8% | -20.2% | 3.9% | -6.9% |
| Net Margin | -13.4% | -13.4% | -22.1% | -18.4% | -61.5% | 12.2% | -7.7% | -1.8% | -0.7% | 3.6% | -15.8% | 4.8% | -4.4% | 3.5% | -22.4% | 6.9% | -9.3% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 3.38 | 3.38 | 2.61 | 1.55 | 1.07 | 1.47 | 2.48 | 1.29 | 0.79 | 0.49 | 0.00 | 0.34 | 0.47 | 0.49 | 0.63 | 0.41 | 0.61 |
| Current Ratio | 0.27 | 0.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-27.1M | $-27.1M | $-29.1M | $380000.00 | $-41.5M | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -50.4% | -50.4% | -63.6% | -39.1% | -93.5% | 10.4% | -61.7% | -7.4% | -1.8% | 10.4% | -43.3% | 10.2% | -11.2% | 8.2% | -75.4% | 16.1% | -25.2% |
| Valuation | |||||||||||||||||
| EV/EBITDA | 18.08 | 18.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.07 | 0.07 | 0.29 | 0.23 | 1.31 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 4.5% | 4.5% | -14.3% | 4.5% | — | 48.2% | 38.6% | 65.6% | 8.7% | 18.6% | -9.9% | -7.7% | 11.4% | -21.8% | -14.9% | 15.2% | — |
| EPS Growth | 49.6% | 49.6% | -2.2% | 70.4% | — | 144.2% | -437.5% | -300.0% | -120.0% | 125.0% | -671.4% | 153.8% | -244.4% | 110.2% | -18.9% | -34.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-88.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.19 → -2.11
Residual
-88.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.